Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin Ethylsuccinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.89 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 0.89 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.89 |
| ▸ | USP2 | O75604 | 3/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.77 |
| ▸ | MLNR | O43193 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | ALB | P02768 | 1/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL8369453 | 0.97 | PGR (0.83) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL28251264 | 0.96 | CYP3A4 (0.96) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| SCHEMBL788111 | 0.95 | PGR (0.87) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| SCHEMBL40640 | 0.95 | PGR (0.87) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL5082211 | 0.94 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL537373 | 0.94 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL7866739 | 0.94 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL18259 | 0.94 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL9118779 | 0.94 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL15665988 | 0.94 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966481-B1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | MIGENIX INC (CA) | 2006-07-19 | — | — | EP | disclosed |
| EP-0925308-B1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH INC (CA) | 2002-06-05 | — | — | EP | disclosed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | disclosed |